Quick Answer
Protalix BioTherapeutics, Inc. reported Total Assets of $82.35 million for fiscal year 2025.
Protalix BioTherapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $82.35M | +12.2% |
| 2024 | $73.42M | -13.0% |
| 2023 | $84.43M | +51.4% |
| 2022 | $55.79M | -24.3% |
| 2021 | $73.67M | +8.4% |
| 2020 | $67.93M | +49.7% |
| 2019 | $45.39M | -25.7% |
| 2018 | $61.13M | -15.3% |
| 2017 | $72.21M | -12.2% |
| 2016 | $82.25M | -15.4% |
| 2015 | $97.25M | +24.1% |
| 2014 | $78.36M | -30.9% |
| 2013 | $113.33M | +44.0% |
| 2012 | $78.73M | +52.0% |
| 2011 | $51.80M | -20.0% |
| 2010 | $64.73M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $82.26M | +33.6% | +4.8% |
| June 30, 2025 | $78.49M | -14.3% | +6.2% |
| March 31, 2025 | $73.89M | -17.7% | +0.6% |
| December 31, 2024 | $73.42M | -13.0% | +19.3% |
| September 30, 2024 | $61.56M | -29.7% | -32.7% |
| June 30, 2024 | $91.54M | +3.5% | +1.9% |
| March 31, 2024 | $89.83M | +35.0% | +6.4% |
| December 31, 2023 | $84.43M | +51.4% | -3.6% |
- Protalix BioTherapeutics, Inc. showed an increase of +12.2% in Total Assets compared to the prior fiscal year.
- Over the 2010–2025 period, Protalix BioTherapeutics, Inc.’s total assets has grown by 27.2% (from $64.73 million to $82.35 million).
- The most recent figure is from Protalix BioTherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: